BioStock: Synact Pharma on expansion into Covid-19

A serious consequence of the Covid-19 infection is severe pneumonia, which can lead to acute respiratory distress syndrome (ARDS) and the subsequent need for respiratory treatment. Earlier this week, SynAct Pharma announced that it intends to position its clinical anti-inflammatory drug candidate AP1189 as an adjunctive therapy in hospitalised patients with Covid-19 infection in order to prevent ARDS. BioStock contacted the company’s CEO Jeppe Øvlesen for a comment.

Read the full interview with Synact Pharma's CEO Jeppe Øvlesen at biostock.se:

https://www.biostock.se/en/synact-pharma-on-expansion-into-covid-19/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se